紫杉醇联合铂类新辅助化疗局部晚期宫颈癌效果及对Smac Survivin MMP-2表达的影响

doi:10.3969/j.issn.1006-6233.2018.03.009

Abstract
Figure/Table
References
Related Citation (5)

Download: PDF (1345 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the clinical effect of paclitaxel combined with platinum neoadjuvant chemotherapy (NACT) in the treatment of locally advanced cervical cancer (LACC) and the influence on the expression of second mitochondria-derived activator of caspase (Smac), apoptosis inhibiting gene (Survivin) and matrix metalloproteinase -2 (MMP-2). Methods: 76 patients with LACC were divided into the study group and the control group by random number table method, 38 cases in each group. Patients in the study group were treated with paclitaxel + cisplatin chemotherapy, while patients in the control group were treated with cisplatin +5- fluorouracil (5-FU) chemotherapy. The short-term curative effect, operation indexes, postoperative lymph node metastasis and the expression of Smac in cervical cancer tissues were compared between the two groups. Changes of serum levels of Survivin and MMP-2 levels before and after treatment were observed, and the incidence of toxic and side reactions was recorded. Results: The response rate of the study group was higher than that of the control group. The operation time, intraoperative blood loss, postoperative lymph node metastasis rate and the positive rate of Smac in the cervical cancer tissues in the study group were shorter / less / lower than those in the control group (P < 0.05). After 2 courses of chemotherapy, serum levels of Survivin and MMP-2 in the two groups were decreased, and the levels in study group were lower than those in the control group (P < 0.05). There was no significant difference in the incidence of toxic and side effects between the two groups (P > 0.05). Conclusion: Paclitaxel combined with platinum NACT is markedly effective in the treatment of LACC. The regimen can reduce the blood loss, shorten the operation time, reduce the expression of Smac, Survivin and MMP-2 and inhibit tumor metastasis. It is conducive to the prognosis of the disease but attention should be paid to toxic and side effects.

Key words： Paclitaxel LACC NACT Smac MMP-2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Zhian
	YI Hongyan

Cite this article:

ZHANG Zhian,YI Hongyan. Effect of Paclitaxel Combined with Platinum Neoadjuvant Chemotherapy on Locally Advanced Cervical Cancer and the Influence on the Expression of Smac Survivin and MMP-2[J]. HeBei Med, 2018, 24(3): 385-389.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2018.03.009 OR http://www.hbyxzzs.cn/EN/Y2018/V24/I3/385

[1] Musaev A, Guzel AB, Khatib G, et al. Assessment of primary radical hysterectomy and neoadjuvant chemotherapy followed by radical hysterectomy in stage IB2, IIA bulky cervical cancer [J]. Eur Gynaecol Oncol, 2015, 36(5): 579-584.
[2] 李凤虎,杨飞月,常建英,等.宫颈癌紫杉醇联合洛铂或顺铂新辅助序贯洛铂或顺铂同步化放疗多中心随机临床研究[J].中华肿瘤防治杂志,2016,23(16):1090~1094.
[3] 谢小妹,李向阳,殷海涛,等.雷替曲塞联合顺铂同步放化疗治疗中晚期宫颈癌[J].中华妇幼临床医学杂志(电子版),2016,12(6):644~650.
[4] 朱丽红,田素青,曲昂,等.早期宫颈癌术后每周紫杉醇＋顺铂同步3 DCRT的Ⅰ期临床研究[J].中华放射肿瘤学杂志,2016,25(8):834~838.
[5] 麻宏亮,张洪涛.化疗联合中药对中晚期非小细胞肺癌患者免疫功能和KPS评分的影响[J].海南医学,2014,25(15):2271~2272.
[6] 李双,李雄,张媛,等.宫颈癌的手术-病理分期和评分系统的建立和验证[J].现代妇产科进展,2016,25(11):801~807.
[7] 张萍,艾斌.实体瘤免疫治疗疗效评价标准[J].国际肿瘤学杂志,2016,43(11):848~851.
[8] 王昕雯,高迎春.奈达铂或顺铂分别联合紫杉醇同步放疗用于中晚期宫颈癌的疗效比较[J].中国药房,2017,28(3):318~320.
[9] 袁秀英,刘燕燕,刘小媚,等.紫杉醇、卡铂化疗联合放疗在中晚期宫颈癌患者中的效果[J].广东医学,2017,38(z1):242~243.
[10] 刘海霞.紫杉醇联合卡铂化疗同步放疗治疗中晚期宫颈癌近期疗效观察[J].山东医药,2017,57(6):83~84.
[11] 田亚萍,王园园,迟宝荣,等.黄芪、丹参酮ⅡA和5－氟尿嘧啶单用及联合应用对人宫颈癌HeLa细胞的体外作用研究[J].中国全科医学,2016,19(9):1081~1085.
[12] 杜鲁豫,陈怀博.新辅助化疗方案联合手术治疗晚期宫颈癌的效果及安全性探讨[J].癌症进展,2016,14(3):245~247,250.
[13] 王静,经莉,胡增艳,等.奈达铂联合紫杉醇新辅助化疗方案在局部晚期宫颈癌患者中的应用效果[J].安徽医学,2016,37(11):1367~1370.
[14] 李翔,鲁艳明,张瑶,等.紫杉醇联合顺铂新辅助化疗在早中期宫颈癌治疗中的临床应用[J].实用药物与临床,2016,19(2):148~151.
[15] Symonds RP, Gourley C, Davidson S, et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial [J]. Lancet Oncol, 2015, 16(15): 1515~1524.
[16] Fratz EJ, Hunter GA, Ferreira GC. Expression of murine 5-aminolevulinate synthase variants causes protoporphyrin IX accumulation and light-induced mammalian cell death [J]. PLo S One, 2014, 9(4):e93078.
[17] 孔丽娟.宫颈癌患者癌组织中基质金属蛋白酶2和9的表达及临床意义[J].中国综合临床,2016,32(3):267~269.
[18] 刘琼珊,张妙清,郑芝祥,等.Smac和Livin的表达与宫颈癌的发生发展相关性分析[J].中国妇幼健康研究,2017,28(4):444~447.